Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Plk1 protects kinetochore-centromere architecture against microtubule pulling forces.

Lera RF, Norman RX, Dumont M, Dennee A, Martin-Koob J, Fachinetti D, Burkard ME.

EMBO Rep. 2019 Aug 30:e48711. doi: 10.15252/embr.201948711. [Epub ahead of print]

PMID:
31468671
2.

Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation.

Pasch CA, Favreau PF, Yueh AE, Babiarz CP, Gillette AA, Sharick JT, Karim MR, Nickel KP, DeZeeuw AK, Sprackling CM, Emmerich PB, DeStefanis RA, Pitera RT, Payne SN, Korkos DP, Clipson L, Walsh CM, Miller D, Carchman EH, Burkard ME, Lemmon KK, Matkowskyj KA, Newton MA, Ong IM, Bassetti MF, Kimple RJ, Skala MC, Deming DA.

Clin Cancer Res. 2019 Sep 1;25(17):5376-5387. doi: 10.1158/1078-0432.CCR-18-3590. Epub 2019 Jun 7.

PMID:
31175091
3.

A physician-scientist preceptorship in clinical and translational research enhances training and mentorship.

Stefely JA, Theisen E, Hanewall C, Scholl L, Burkard ME, Huttenlocher A, Yu JJ.

BMC Med Educ. 2019 Mar 27;19(1):89. doi: 10.1186/s12909-019-1523-0.

4.

Visualization of Sequential Treatments in Metastatic Breast Cancer.

Rocque GB, Kandhare PG, Williams CP, Nakhmani A, Azuero A, Burkard ME, Forero A, Bhatia S, Kenzik KM.

JCO Clin Cancer Inform. 2019 Mar;3:1-8. doi: 10.1200/CCI.18.00095.

5.

Polo-like kinase 4 maintains centriolar satellite integrity by phosphorylation of centrosomal protein 131 (CEP131).

Denu RA, Sass MM, Johnson JM, Potts GK, Choudhary A, Coon JJ, Burkard ME.

J Biol Chem. 2019 Apr 19;294(16):6531-6549. doi: 10.1074/jbc.RA118.004867. Epub 2019 Feb 25.

PMID:
30804208
6.

A randomized trial of immediate versus delayed survivorship care plan receipt on patient satisfaction and knowledge of diagnosis and treatment.

Tevaarwerk AJ, Hocking WG, Buhr KA, Gribble M, Seaborne LA, Wisinski KB, Burkard ME, Yen T, Wiegmann DA, Sesto ME.

Cancer. 2019 Mar 15;125(6):1000-1007. doi: 10.1002/cncr.31875. Epub 2019 Jan 28.

PMID:
30690714
7.

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.

Fricke SL, Payne SN, Favreau PF, Kratz JD, Pasch CA, Foley TM, Yueh AE, Van De Hey DR, Depke MG, Korkos DP, Sha GC, DeStefanis RA, Clipson L, Burkard ME, Lemmon KK, Parsons BM, Kenny PA, Matkowskyj KA, Newton MA, Skala MC, Deming DA.

Mol Cancer Ther. 2019 Feb;18(2):346-355. doi: 10.1158/1535-7163.MCT-18-0510. Epub 2018 Nov 13.

PMID:
30425131
8.

Shared Knowledge in Precision Cancer Care.

Burkard ME, Golden RN.

WMJ. 2018 Oct;117(4):178-179. No abstract available.

9.

MACROD2, an Original Cause of CIN?

Jin N, Burkard ME.

Cancer Discov. 2018 Aug;8(8):921-923. doi: 10.1158/2159-8290.CD-18-0674.

10.

Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma.

Denu RA, Shabbir M, Nihal M, Singh CK, Longley BJ, Burkard ME, Ahmad N.

Mol Cancer Res. 2018 Mar;16(3):517-527. doi: 10.1158/1541-7786.MCR-17-0197. Epub 2018 Jan 12.

11.

Photosensitive lichenoid skin reaction to capecitabine.

Shah RA, Bennett DD, Burkard ME.

BMC Cancer. 2017 Dec 19;17(1):866. doi: 10.1186/s12885-017-3882-4.

12.

PP2A-B' holoenzyme substrate recognition, regulation and role in cytokinesis.

Wu CG, Chen H, Guo F, Yadav VK, Mcilwain SJ, Rowse M, Choudhary A, Lin Z, Li Y, Gu T, Zheng A, Xu Q, Lee W, Resch E, Johnson B, Day J, Ge Y, Ong IM, Burkard ME, Ivarsson Y, Xing Y.

Cell Discov. 2017 Aug 8;3:17027. doi: 10.1038/celldisc.2017.27. eCollection 2017.

13.

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ.

Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5.

14.

Using cancer genomics to guide clinical decisions.

Burkard ME, Deming DA, Lauring J.

Cancer. 2017 Apr 15;123(8):1288-1291. doi: 10.1002/cncr.30640. Epub 2017 Mar 2. No abstract available.

15.

Accuracy and Thoroughness of Treatment Summaries Provided as Part of Survivorship Care Plans Prepared by Two Cancer Centers.

Tevaarwerk AJ, Hocking WG, Zeal JL, Gribble M, Seaborne L, Buhr KA, Wisinski KB, Burkard ME, Wiegmann DA, Sesto ME.

J Oncol Pract. 2017 May;13(5):e486-e495. doi: 10.1200/JOP.2016.018648. Epub 2017 Feb 21.

16.

Tuning Chromosomal Instability to Optimize Tumor Fitness.

Burkard ME, Weaver BA.

Cancer Discov. 2017 Feb;7(2):134-136. doi: 10.1158/2159-8290.CD-16-1415.

17.

Synchronous Bilateral Breast Cancer in a Patient With Nager Syndrome.

Denu RA, Burkard ME.

Clin Breast Cancer. 2017 Jun;17(3):e151-e153. doi: 10.1016/j.clbc.2016.12.009. Epub 2017 Jan 5. No abstract available.

18.

Anillin Phosphorylation Controls Timely Membrane Association and Successful Cytokinesis.

Kim H, Johnson JM, Lera RF, Brahma S, Burkard ME.

PLoS Genet. 2017 Jan 12;13(1):e1006511. doi: 10.1371/journal.pgen.1006511. eCollection 2017 Jan.

19.

Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.

Rampurwala M, Wisinski KB, Burkard ME, Ehsani S, O'Regan RM, Carmichael L, Kim K, Kolesar J, Tevaarwerk AJ.

Invest New Drugs. 2017 Feb;35(1):87-94. doi: 10.1007/s10637-016-0403-2. Epub 2016 Nov 8.

20.

Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study.

Wisinski KB, Xu W, Tevaarwerk AJ, Saha S, Kim K, Traynor A, Dietrich L, Hegeman R, Patel D, Blank J, Harter J, Burkard ME.

Clin Breast Cancer. 2016 Aug;16(4):256-61. doi: 10.1016/j.clbc.2016.03.005. Epub 2016 Mar 31.

21.

Decoding Polo-like kinase 1 signaling along the kinetochore-centromere axis.

Lera RF, Potts GK, Suzuki A, Johnson JM, Salmon ED, Coon JJ, Burkard ME.

Nat Chem Biol. 2016 Jun;12(6):411-8. doi: 10.1038/nchembio.2060. Epub 2016 Apr 4.

22.

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.

Wisinski KB, Tevaarwerk AJ, Burkard ME, Rampurwala M, Eickhoff J, Bell MC, Kolesar JM, Flynn C, Liu G.

Clin Cancer Res. 2016 Jun 1;22(11):2659-67. doi: 10.1158/1078-0432.CCR-15-2365. Epub 2016 Mar 29.

23.

The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation.

Lasek AL, McPherson BM, Trueman NG, Burkard ME.

PLoS One. 2016 Feb 26;11(2):e0150225. doi: 10.1371/journal.pone.0150225. eCollection 2016.

24.

Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer.

Denu RA, Zasadil LM, Kanugh C, Laffin J, Weaver BA, Burkard ME.

BMC Cancer. 2016 Jan 29;16:47. doi: 10.1186/s12885-016-2083-x.

25.

Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer.

Choudhary A, Zachek B, Lera RF, Zasadil LM, Lasek A, Denu RA, Kim H, Kanugh C, Laffin JJ, Harter JM, Wisinski KB, Saha S, Weaver BA, Burkard ME.

Mol Cancer Ther. 2016 Jan;15(1):48-59. doi: 10.1158/1535-7163.MCT-15-0527. Epub 2015 Nov 19.

26.

Centralspindlin assembly and 2 phosphorylations on MgcRacGAP by Polo-like kinase 1 initiate Ect2 binding in early cytokinesis.

Kim H, Guo F, Brahma S, Xing Y, Burkard ME.

Cell Cycle. 2014;13(18):2952-61. doi: 10.4161/15384101.2014.947201.

27.

Update on adjuvant chemotherapy for early breast cancer.

Rampurwala MM, Rocque GB, Burkard ME.

Breast Cancer (Auckl). 2014 Oct 8;8:125-33. doi: 10.4137/BCBCR.S9454. eCollection 2014. Review.

28.

"TRIMing" the patient population to increase the benefit of mTOR inhibition.

Robins HI, Burkard ME, Halberg RB.

J Natl Cancer Inst. 2014 Apr 28;106(5). pii: dju095. doi: 10.1093/jnci/dju095. No abstract available.

PMID:
24777109
29.

Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles.

Zasadil LM, Andersen KA, Yeum D, Rocque GB, Wilke LG, Tevaarwerk AJ, Raines RT, Burkard ME, Weaver BA.

Sci Transl Med. 2014 Mar 26;6(229):229ra43. doi: 10.1126/scitranslmed.3007965.

30.

Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

Burkard ME, Wisinski KB, Njiaju UO, Donohue S, Hegeman R, Stella A, Mansky P, Shah V, Goggins T, Qamar R, Dietrich L, Kim K, Traynor AM, Tevaarwerk AJ.

Clin Breast Cancer. 2014 Jun;14(3):205-11. doi: 10.1016/j.clbc.2013.10.018. Epub 2013 Oct 26.

31.

Interphase cytofission maintains genomic integrity of human cells after failed cytokinesis.

Choudhary A, Lera RF, Martowicz ML, Oxendine K, Laffin JJ, Weaver BA, Burkard ME.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13026-31. doi: 10.1073/pnas.1308203110. Epub 2013 Jul 22.

32.

High mitotic activity of Polo-like kinase 1 is required for chromosome segregation and genomic integrity in human epithelial cells.

Lera RF, Burkard ME.

J Biol Chem. 2012 Dec 14;287(51):42812-25. doi: 10.1074/jbc.M112.412544. Epub 2012 Oct 27.

33.

The final link: tapping the power of chemical genetics to connect the molecular and biologic functions of mitotic protein kinases.

Lera RF, Burkard ME.

Molecules. 2012 Oct 17;17(10):12172-86. doi: 10.3390/molecules171012172. Review.

34.

Enabling and disabling polo-like kinase 1 inhibition through chemical genetics.

Burkard ME, Santamaria A, Jallepalli PV.

ACS Chem Biol. 2012 Jun 15;7(6):978-81. doi: 10.1021/cb200551p. Epub 2012 Mar 20.

35.

Aromatase inhibitors and calcium absorption in early stage breast cancer.

Tevaarwerk A, Burkard ME, Wisinski KB, Shafer MM, Davis LA, Gogineni J, Crone E, Hansen KE.

Breast Cancer Res Treat. 2012 Jul;134(1):245-51. doi: 10.1007/s10549-012-1982-z. Epub 2012 Feb 18.

36.

Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.

Rocque G, Onitilo A, Engel J, Pettke E, Boshoven A, Kim K, Rishi S, Waack B, Wisinski KB, Tevaarwerk A, Burkard ME.

Breast Cancer Res Treat. 2012 Jan;131(2):713-21. doi: 10.1007/s10549-011-1862-y. Epub 2011 Nov 8.

37.

Validating cancer drug targets through chemical genetics.

Burkard ME, Jallepalli PV.

Biochim Biophys Acta. 2010 Dec;1806(2):251-7. doi: 10.1016/j.bbcan.2010.08.002. Epub 2010 Aug 12. Review.

38.

In the interest of full disclosure.

Burkard ME, Tevaarwerk AJ, Wisinski KB.

Lancet Oncol. 2010 Apr;11(4):314-5; author reply 315. doi: 10.1016/S1470-2045(10)70044-9. No abstract available.

PMID:
20359661
39.

Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells.

Burkard ME, Maciejowski J, Rodriguez-Bravo V, Repka M, Lowery DM, Clauser KR, Zhang C, Shokat KM, Carr SA, Yaffe MB, Jallepalli PV.

PLoS Biol. 2009 May 5;7(5):e1000111. doi: 10.1371/journal.pbio.1000111. Epub 2009 May 26.

40.

Polo kinase and cytokinesis initiation in mammalian cells: harnessing the awesome power of chemical genetics.

Randall CL, Burkard ME, Jallepalli PV.

Cell Cycle. 2007 Jul 15;6(14):1713-7. Epub 2007 May 7. Review.

PMID:
17630508
41.

Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells.

Burkard ME, Randall CL, Larochelle S, Zhang C, Shokat KM, Fisher RP, Jallepalli PV.

Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4383-8. Epub 2007 Mar 6.

42.
43.

Sheared Aanti.Aanti base pairs in a destabilizing 2 x 2 internal loop: the NMR structure of 5'(rGGCAAGCCU)2.

Znosko BM, Burkard ME, Schroeder SJ, Krugh TR, Turner DH.

Biochemistry. 2002 Dec 17;41(50):14969-77.

PMID:
12475246
44.

Thermodynamics of RNA internal loops with a guanosine-guanosine pair adjacent to another noncanonical pair.

Burkard ME, Xia T, Turner DH.

Biochemistry. 2001 Feb 27;40(8):2478-83.

PMID:
11327869
45.

The energetics of small internal loops in RNA.

Schroeder SJ, Burkard ME, Turner DH.

Biopolymers. 1999-2000;52(4):157-67. Review.

PMID:
11295748
46.
47.

Predicting oligonucleotide affinity to nucleic acid targets.

Mathews DH, Burkard ME, Freier SM, Wyatt JR, Turner DH.

RNA. 1999 Nov;5(11):1458-69.

48.

Thermodynamics of single mismatches in RNA duplexes.

Kierzek R, Burkard ME, Turner DH.

Biochemistry. 1999 Oct 26;38(43):14214-23.

PMID:
10571995
49.
50.

Thermodynamic parameters for an expanded nearest-neighbor model for formation of RNA duplexes with Watson-Crick base pairs.

Xia T, SantaLucia J Jr, Burkard ME, Kierzek R, Schroeder SJ, Jiao X, Cox C, Turner DH.

Biochemistry. 1998 Oct 20;37(42):14719-35.

PMID:
9778347

Supplemental Content

Loading ...
Support Center